SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focused on DelMar Pharmaceuticals recent update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
“We find this trial update very encouraging, as DMPI remains on track with their dose-escalation study and overall clinical trial program for VAL-083. We anticipate DMPI advancing VAL-083 toward registration directed trials in refractory glioblastoma in 1H14E,” stated Ajay Tandon, CEO of SeeThruEquity.
The report is available to SeeThruEquity Select Members on SeeThruEquity's website and can be directly accessed here: DMPI VAL-083 Update. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The report will also available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street. For more information visit www.seethruequity.com.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. For more information, please visit http://www.delmarpharma.com.
Contacts:
Ajay Tandon, 646-495-0939
